Page 7 - Fred Schwarzer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., as Chief Medical Officer MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical Officer, effective today. Dr. Takimoto will be responsible for global development of IGM’s clinical pipeline of proprietary IgM antibodies. He joins IGM with 30 years of experience i...

Through a multi-institutional study, scientists have developed a new hybrid antibody that can neutralize over 20 variants of the SARS-CoV-2 virus, and shows promise as a potential treatment against COVID-19.

A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The University of Texas Health Science Center at Houston (UTHealth), The University of Texas Medical Branch at Galveston (UTMB Health), the University of Houston, and IGM Biosciences, Inc.

A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The University of Texas Health Science Center at Houston (UTHealth), The University of Texas Medical Branch at Galveston (UTMB Health), the University of Houston, and IGM Biosciences, Inc.

IGM Biosciences Appoints George Gauthier as Chief Commercial Officer Mr. Gauthier Brings 20 Years of Global Commercial Experience in the Life Sciences Industry April 12, 2021 07:00 ET | Source: IGM Biosciences IGM Biosciences Mountain View, California, UNITED STATES MOUNTAIN VIEW, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of George A. Gauthier to the newly created position of Ch...